We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
USA - August 16 2012
In welcomed news for biotechnology and pharmaceutical companies, the U.S. Court of Appeals for the Federal Circuit held claims to isolated DNA molecules and methods of screening potential anti-cancer therapeutics are patentable subject matter in view of the U.S. Supreme Court decision in Prometheus.
